Takeda exec plans sale of 34,535 ADSs under Rule 144

Takeda’s Chief Transformation Officer files a Rule 144 notice to sell 34,535 ADSs, after a prior tax-related sale of 47,586 ADSs.

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD (TAK) has a notice of proposed sale under Rule 144 for American Depositary Shares by Chief Transformation Officer Lauren Rusckowski Duprey. The notice covers 34,535 ADSs, which were acquired through vested Restricted Stock Unit Awards on July 30, 2024.

The broker listed is Interactive Brokers LLC, with the ADSs indicated for trading on the NYSE. The notice also reports that over the past three months, 47,586 ADSs were sold on July 13, 2026 for $813,720.60, with the remark that this earlier sale was made to satisfy tax obligations related to share vesting effective that date.

Key Figures

ADSs to be sold: 34,535 ADSs ADSs sold in past 3 months: 47,586 ADSs Sale proceeds in past 3 months: $813,720.60 +3 more

6 metrics

ADSs to be sold 34,535 ADSs Proposed sale under Rule 144 by Chief Transformation Officer Lauren Rusckowski Duprey

ADSs sold in past 3 months 47,586 ADSs Sale on July 13, 2026 reported in the three-month sales section

Sale proceeds in past 3 months $813,720.60 Total consideration for 47,586 ADSs sold on July 13, 2026

Date ADSs to be sold September 10, 2026 Proposed sale date shown in the securities information section

RSU vesting date for ADSs July 30, 2024 Acquisition date of ADSs via Restricted Stock Unit Awards – Vested

Notice date September 10, 2026 Date of Rule 144 notice signature

Key Terms

Rule 144, American Depositary Shares (ADSs), Restricted Stock Unit Awards, compensation

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC..."

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards financial

"Restricted Stock Unit Awards - Vested | Takeda Pharmaceutical Company Limited"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

compensation financial

"07/30/2024 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TAK by Lauren Rusckowski Duprey disclose?

It discloses a proposed Rule 144 sale of 34,535 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited by Chief Transformation Officer Lauren Rusckowski Duprey, with the ADSs acquired from vested Restricted Stock Unit Awards on July 30, 2024.

How many Takeda (TAK) ADSs were sold in the past three months?

The notice reports that 47,586 ADSs were sold on July 13, 2026 for total consideration of $813,720.60. A remark states this sale was conducted to satisfy tax obligations in connection with share vesting effective July 13, 2026.

What type of security is involved in the Takeda (TAK) Form 144 filing?

The security is American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited. The filing indicates these ADSs are to be traded on the NYSE, with Interactive Brokers LLC listed as the broker handling the transaction.

How were the Takeda (TAK) ADSs to be sold under Form 144 acquired?

The 34,535 ADSs covered by the notice were acquired through Restricted Stock Unit Awards – Vested on July 30, 2024, and the transaction is described as related to compensation from Takeda Pharmaceutical Company Limited.

Who is the insider involved in the Takeda (TAK) Form 144 and what is their role?

The person for whose account the securities are to be sold is Lauren Rusckowski Duprey, identified in the filing as Chief Transformation Officer of Takeda Pharmaceutical Company Limited, in connection with the Rule 144 notice for ADS sales.

Which broker is listed for the Takeda (TAK) ADS sale in the Form 144 filing?

The broker listed is Interactive Brokers LLC, with the ADSs indicated for trading on the NYSE. The securities information section associates Interactive Brokers with the 34,535 ADSs to be sold under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 08:00 AM EDT Accepted by SEC EDGAR 09/10/2026 - 08:00 AM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977746
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number	001-38757
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo JAPAN 103-8668
Phone	81-3-3278-2306
Name of Person for Whose Account the Securities are To Be Sold	Lauren Rusckowski Duprey
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Chief Transformation Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich, CT 06830	34535	634407.95	198318946	09/10/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/30/2024	Restricted Stock Unit Awards - Vested	Takeda Pharmaceutical Company Limited			34535	07/30/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Lauren Duprey Rusckowski 45-55 Hayden Avenue Lexington, MA 02139	ADSs	07/13/2026	47586	813720.60

144: Remarks and Signature

Remarks	Sale during the past 3 months was conducted in order to satisfy tax obligations in connection with share vesting effective July 13, 2026.
Date of Notice	09/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Samuel Ntonme, by power of attorney for Lauren Duprey Rusckowski
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)